Abstract: There is disclosed vectors for treating lipodystrophy and vectors for use in the treatment of lipodystrophy. In particular, the disclosure relates to gene therapy vectors capable of expressing UCP1 for the treatment of lipodystrophy.

Abstract: Use of a method for reduction of heavy end formation and catalyst loss in a hydroformylation process, wherein the method comprises the steps; a) Reacting an olefin and syngas in a reactor assembly (1) utilizing at least one catalyst and at least one ligand, b) Separating an obtained aldehyde from a mixture of aldehyde, catalyst, ligand and early heavy ends in a distillation unit (2), c) Entering the mixture of catalyst, ligand, early heavy ends and rest aldehyde into a short residence time evaporator unit (3) having at least a first rest aldehyde stripper stage (3a) and at least one last early heavy ends stripper stage (3b). Said evaporator units (3) being of a falling film and/or wiped film type, d) That the catalyst/ligand mixture from a lower end (3b1) of the at least one last early heavy ends stripping stage (3b) is entered into a cooling unit (4) immediately after stripping of early heavy ends.

Abstract: The present invention refers to a method for reducing heavy end formation and catalyst loss in a continuous hydroformylation process, where an olefin or an olefin mixture is reacted with carbon monoxide and hydrogen in a reactor assembly (1) in the presence of a rhodium complex catalyst, comprising at least one organobisphosphite ligand, in order to produce an aldehyde. Said method comprising the addition of an epoxide to the reaction mixture and the continuous or discontinuous removal of early heavy ends.

Abstract: The invention concerns a brazing sheet comprising a core layer (5) and a braze cladding, said core layer (5) being aluminium or an aluminium alloy, said braze cladding comprising (a) a flux composite layer (2), which flux composite layer comprises a matrix of aluminium or an aluminium alloy, said matrix containing flux particles; (b) at least one filler alloy layer (1) not containing flux particles; and, (c) an aluminium or aluminium alloy layer (3) not containing flux particles, said layer forming the outermost surface of at least one side of the brazing sheet, wherein the flux composite layer (a) is positioned between said filler alloy layer (b) and said aluminium or aluminium alloy layer (c). The invention further concerns a method for its manufacturing, a cladding plate, use of the brazing sheet and a brazed heat exchanger.

Abstract: The invention concerns a brazing sheet comprising a core layer (5) and a braze cladding, said core layer (5) being aluminium or an aluminium alloy, said braze cladding comprising (a) a flux composite layer (2), which flux composite layer comprises a matrix of aluminium or an aluminium alloy, said matrix containing flux particles; (b) at least one filler alloy layer (1) not containing flux particles; and, (c) an aluminium or aluminium alloy layer (3) not containing flux particles, said layer forming the outermost surface of at least one side of the brazing sheet, wherein the flux composite layer (a) is positioned between said filler alloy layer (b) and said aluminium or aluminium alloy layer (c). The invention further concerns a method for its manufacturing, a cladding plate, use of the brazing sheet and a brazed heat exchanger.

Abstract: The present invention relates to a process for purification of recombinant alpha-mannosidase, a process for production of alpha-mannosidase, a composition comprising alpha-mannosidase, use of the composition as a medicament, use as a medicament for the treatment of alpha-mannosidosis and a method of treating alpha-mannosidosis and/or alleviating the symptoms of alpha-mannosidosis.

Abstract: The present invention comprises a method of concentrating a composition comprising a polypeptide of interest and the use of such concentrated composition for the treatment of diseases in mammals, in particular by subcutaneous injection.

Abstract: The invention provides a treatment of mesothelioma, especially malignant pleural mesothelioma, using an estrogen receptor ? subtype (ER?) agonist, wherein the treatment comprises administering the ER? agonist to the patient, and then after a time, t, of up to 24 hours; administering a platinum-containing anti-cancer drug to the patient. The invention also provides an ER? agonist and a platinum-containing anti-cancer drug for use in the treatment of mesothelioma in a patient, wherein the treatment comprises administering the ER? agonist to the patient, and then after a time, t, of up to 24 hours, administering the platinum-containing anti-cancer drug to the patient; and a kit comprising a platinum-containing anti-cancer drug and an ER? agonist.

Abstract: The present invention relates to a process for purification of recombinant alpha-mannosidase, a process for production of alpha-mannosidase, a composition comprising alpha-mannosidase, use of the composition as a medicament, use as a medicament for the treatment of alpha-mannosidosis and a method of treating alpha-mannosidosis and/or alleviating the symptoms of alpha-mannosidosis.

Abstract: The present invention comprises a method of concentrating a composition comprising a polypeptide of interest and the use of such concentrated composition for the treatment of diseases in mammals, in particular by subcutaneous injection.

Abstract: The present invention comprises a method of concentrating a composition comprising a polypeptide of interest and the use of such a concentrated composition for the treatment of diseases in mammals, in particular by subcutaneous injection.

Abstract: The invention provides a treatment of mesothelioma, especially malignant pleural mesothelioma, using an estrogen receptor ? subtype (ER?) agonist, wherein the treatment comprises administering the ER? agonist to the patient, and then after a time, t, of up to 24 hours; administering a platinum-containing anti-cancer drug to the patient. The invention also provides an ER? agonist and a platinum-containing anti-cancer drug for use in the treatment of mesothelioma in a patient, wherein the treatment comprises administering the ER? agonist to the patient, and then after a time, t, of up to 24 hours, administering the platinum-containing anti-cancer drug to the patient; and a kit comprising a platinum-containing anti-cancer drug and an ER? agonist.

Abstract: The present invention comprises a method of concentrating a composition comprising a polypeptide of interest and the use of such concentrated composition for the treatment of diseases in mammals, in particular by subcutaneous injection.

Abstract: The present invention relates to a process for purification of recombinant alpha-mannosidase, a process for production of alpha-mannosidase, a composition comprising alpha-mannosidase, use of the composition as a medicament, use as a medicament for the treatment of alpha-mannosidosis and a method of treating alpha-mannosidosis and/or alleviating the symptoms of alpha-mannosidosis.

Abstract: The present invention relates to a process for purification of recombinant alpha-mannosidase, a process for production of alpha-mannosidase, a composition comprising alpha-mannosidase, use of the composition as a medicament, use as a medicament for the treatment of alpha-mannosidosis and a method of treating alpha-mannosidosis and/or alleviating the symptoms of alpha-mannosidosis.

Abstract: The present invention comprises a method of concentrating a composition comprising a polypeptide of interest and the use of such a concentrated composition for the treatment of diseases in mammals, in particular by subcutaneous injection.

Abstract: The present invention comprises a method of concentrating a composition comprising a polypeptide of interest and the use of such a concentrated composition for the treatment of diseases in mammals, in particular by subcutaneous injection.

Abstract: The invention discloses a sterilization device (1), to sterilize media, equipment and/or decontamination of waste material, said sterilization device (1) comprising a chamber (2), at least one exhaust line (6) arranged to said chamber (2) and at least one gas generator arranged to said chamber (2), at least two sterile filters (8a, 8b) arranged in series in the exhaust line (6), at least one vacuum means (7) connected to the chamber (2) via said exhaust line (6) and said at least two filters (8a, 8b). At least one heating means (9) is arranged to said exhaust line (6) between said two sterile filters (8a, 8b) in order to vaporize condensate that develops between the filters. Furthermore, it is disclosed a sterilization process for sterilization of media, equipment and/or decontamination of waste material, a vaporizing system (12) of a sterilization device and use of such a vaporizing system (12) in a sterilization device.

Abstract: The present invention relates to a process for purification of recombinant alpha-mannosidase, a process for production of alpha-mannosidase, a composition comprising alpha-mannosidase, use of the composition as a medicament, use as a medicament for the treatment of alpha-mannosidosis and a method of treating alpha-mannosidosis and/or alleviating the symptoms of alpha-mannosidosis.

Abstract: The present invention comprises a method of concentrating a composition comprising a polypeptide of interest and the use of such a concentrated composition for the treatment of diseases in mammals, in particular by subcutaneous injection.